Polyphron grows living human heart tissue in an automated foundry and uses it to teach AI what a drug will do next.
An MRI in late 2023 found a mass on Matthew Osman's pancreas. It turned out to be benign, but the months of not knowing made him ask why medicine still cannot predict what happens inside the human body. Today, his company Polyphron grows living human heart tissue in an automated foundry and uses it to teach AI what a drug will do next, backed by a fresh $20M. Find out why Osman believes the real bottleneck in AI-driven biology has nothing to do with generating ideas.